Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.31 |
| ▸ | IL1RN | P18510 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31355505 | 0.85 | ACHE (0.49) | ACHEKDM4EIL1RNERAP2ERAP1 | |
| SCHEMBL689641 | 0.85 | ACHE (0.49) | ACHEKDM4EIL1RNERAP2ERAP1 | |
| SCHEMBL14142254 | 0.81 | ACHE (0.45) | ACHEKDM4E | |
| SCHEMBL5951566 | 0.81 | ACHE (0.46) | ACHEKDM4EIL1RNERAP2ERAP1 | |
| SCHEMBL5953255 | 0.77 | ACHE (0.41) | ACHEKDM4E | |
| SCHEMBL14142398 | 0.77 | ACHE (0.76) | ACHEKDM4E | |
| SCHEMBL5953283 | 0.77 | ACHE (0.41) | ACHEKDM4E | |
| SCHEMBL5952434 | 0.74 | ACHE (0.50) | ACHE | |
| SCHEMBL23891611 | 0.72 | ACHE (0.49) | ACHE | |
| SCHEMBL5951734 | 0.70 | HSP90AB1 (0.43) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963347-B1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7550544-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550544-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550544-B2 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1963347-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents, Inc., A Corporation of the State of Delaware (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070041-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135595-A1 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135595-A1 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135595-A1 | Halogen substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS, INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135595-A1 | Halogen substituted metallocene compounds for olefin polymerization | AP2M1, AP1M1, CPNE4 | ACHE 4379/4885KDM4E 1027/4885ABCC9 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.